Development of new outcome measures for adult SMA type III and IV: a multimodal longitudinal study
- PMID: 33388927
- DOI: 10.1007/s00415-020-10332-5
Development of new outcome measures for adult SMA type III and IV: a multimodal longitudinal study
Abstract
Objective: The aim of this study was the comprehensive characterisation of longitudinal clinical, electrophysiological and neuroimaging measures in type III and IV adult spinal muscular atrophy (SMA) with a view to propose objective monitoring markers for future clinical trials.
Methods: Fourteen type III or IV SMA patients underwent standardised assessments including muscle strength testing, functional evaluation (SMAFRS and MFM), MUNIX (abductor pollicis brevis, APB; abductor digiti minimi, ADM; deltoid; tibialis anterior, TA; trapezius) and quantitative cervical spinal cord MRI to appraise segmental grey and white matter atrophy. Patients underwent a follow-up assessment with the same protocol 24 months later. Longitudinal comparisons were conducted using the Wilcoxon-test for matched data. Responsiveness was estimated using standardized response means (SRM) and a composite score was generated based on the three most significant variables.
Results: Significant functional decline was observed based on SMAFRS (p = 0.019), pinch and knee flexion strength (p = 0.030 and 0.027), MUNIX and MUSIX value in the ADM (p = 0.0006 and 0.043) and in TA muscle (p = 0.025). No significant differences were observed based on cervical MRI measures. A significant reduction was detected in the composite score (p = 0.0005, SRM = -1.52), which was the most responsive variable and required a smaller number of patients than single variables in the estimation of sample size for clinical trials.
Conclusions: Quantitative strength testing, SMAFRS and MUNIX readily capture disease progression in adult SMA patients. Composite multimodal scores increase predictive value and may reduce sample size requirements in clinical trials.
Keywords: Adult SMA; Clinical trial; Longitudinal progression; MUNIX; Outcome measures.
Similar articles
-
The motor unit number index (MUNIX) profile of patients with adult spinal muscular atrophy.Clin Neurophysiol. 2018 Nov;129(11):2333-2340. doi: 10.1016/j.clinph.2018.08.025. Epub 2018 Sep 13. Clin Neurophysiol. 2018. PMID: 30248623 Clinical Trial.
-
Motor unit number index: A potential electrophysiological biomarker for pediatric spinal muscular atrophy.Muscle Nerve. 2021 Oct;64(4):445-453. doi: 10.1002/mus.27372. Epub 2021 Sep 1. Muscle Nerve. 2021. PMID: 34255873
-
Motor unit number index in children with later-onset spinal muscular atrophy.Muscle Nerve. 2020 Nov;62(5):633-637. doi: 10.1002/mus.26909. Epub 2020 May 24. Muscle Nerve. 2020. PMID: 32369629
-
Motor unit number index (MUNIX) in children and adults with 5q-spinal muscular atrophy: Variability and clinical correlations.Neuromuscul Disord. 2021 Jun;31(6):498-504. doi: 10.1016/j.nmd.2021.02.019. Epub 2021 Feb 28. Neuromuscul Disord. 2021. PMID: 33824074
-
Does the MUNIX Method Reflect Clinical Dysfunction in Amyotrophic Lateral Sclerosis: A Practical Experience.Medicine (Baltimore). 2016 May;95(19):e3647. doi: 10.1097/MD.0000000000003647. Medicine (Baltimore). 2016. PMID: 27175687 Free PMC article.
Cited by
-
Biomarkers of therapeutic efficacy in adolescents and adults with 5q spinal muscular atrophy: a systematic review.Acta Neurol Belg. 2023 Oct;123(5):1735-1745. doi: 10.1007/s13760-022-02028-6. Epub 2022 Jul 21. Acta Neurol Belg. 2023. PMID: 35861914
-
Psychometric Characteristics of the Motor Function Measure in Neuromuscular Diseases: A Systematic Review1.J Neuromuscul Dis. 2023;10(3):301-314. doi: 10.3233/JND-230001. J Neuromuscul Dis. 2023. PMID: 37125561 Free PMC article.
-
Application Value of the Motor Unit Number Index in Patients With Kennedy Disease.Front Neurol. 2021 Dec 21;12:705816. doi: 10.3389/fneur.2021.705816. eCollection 2021. Front Neurol. 2021. PMID: 34992574 Free PMC article.
-
An exploratory qualitative assessment of patient and clinician perspectives on patient-reported outcome measures and disease-modifying therapies in adults with spinal muscular atrophy.J Rehabil Med. 2025 Jan 14;57:jrm41254. doi: 10.2340/jrm.v57.41254. J Rehabil Med. 2025. PMID: 39810476 Free PMC article.
-
Validation of motor and functional scales for the evaluation of adult patients with 5q spinal muscular atrophy.Eur J Neurol. 2022 Dec;29(12):3666-3675. doi: 10.1111/ene.15542. Epub 2022 Sep 13. Eur J Neurol. 2022. PMID: 36047967 Free PMC article.
References
-
- Lefebvre S, Bürglen L, Reboullet S et al (1995) Identification and characterization of a spinal muscular atrophy-determining gene. Cell 80:155–165 - PubMed
-
- Munsat TL, Davies KE (1992) International SMA consortium meeting (26-28 June 1992, Bonn, Germany). Neuromuscul Disord NMD 1992(2):423–428
-
- Wadman RI, Wijngaarde CA, Stam M et al (2018) Muscle strength and motor function throughout life in a cross-sectional cohort of 180 patients with spinal muscular atrophy types 1c–4. Eur J Neurol 25:512–518 - PubMed
-
- Wang CH, Finkel RS, Bertini ES et al (2007) Consensus statement for standard of care in spinal muscular atrophy. J Child Neurol 22:1027–1049 - PubMed
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources